Skip to main content
Search
section
Global
News
Careers
Language & Country Selector for Desktop
United States
|
en
Choose Location
Americas
Asia Pacific
Europe
International
Middle East & Africa
Argentina |
es
Brazil |
pt
Canada |
en
Canada |
fr
Central America |
es
Colombia |
es
Latin America |
es
Mexico |
es
United States |
en
Venezuela |
es
Australia |
en
Bangladesh |
en
Hong Kong S.A.R. |
zh
India |
en
Indonesia |
en
Japan |
ja
Korea |
ko
Mainland China |
zh
Malaysia |
en
Pakistan |
en
Philippines |
en
Taiwan |
zh
Austria |
de
Belgium |
fr
Belgium |
nl
Bulgaria |
bg
Czech Republic |
cs
Czech Republic |
en
Denmark |
da
Estonia |
et
Finland |
fi
France |
fr
Germany |
de
Greece |
el
Hungary |
hu
Ireland |
en
Italy |
it
Latvia |
lv
Lithuania |
lt
Netherlands |
nl
Norway |
no
Poland |
pl
Portugal |
pt
Romania |
ro
Russia |
ru
Serbia |
sr
Singapore |
en
Slovakia |
sk
Spain |
es
Sweden |
sv
Switzerland |
de
Switzerland |
fr
United Kingdom |
en
Global |
en
Novartis Foundation |
en
Sandoz |
en
Egypt |
en
South Africa |
en
Turkey |
tr
Language & Country Selector for Mobile
United States
Choose Location
americas
Americas
Asia Pacific
Europe
International
Middle East & Africa
Argentina |
es
Australia |
en
Austria |
de
Bangladesh |
en
Belgium |
fr
Belgium |
nl
Brazil |
pt
Bulgaria |
bg
Canada |
en
Canada |
fr
Central America |
es
Colombia |
es
Czech Republic |
cs
Czech Republic |
en
Denmark |
da
Egypt |
en
Estonia |
et
Finland |
fi
France |
fr
Germany |
de
Global |
en
Greece |
el
Hong Kong S.A.R. |
zh
Hungary |
hu
India |
en
Indonesia |
en
Ireland |
en
Italy |
it
Japan |
ja
Korea |
ko
Latin America |
es
Latvia |
lv
Lithuania |
lt
Mainland China |
zh
Malaysia |
en
Mexico |
es
Netherlands |
nl
Norway |
no
Novartis Foundation |
en
Pakistan |
en
Philippines |
en
Poland |
pl
Portugal |
pt
Romania |
ro
Russia |
ru
Sandoz |
en
Serbia |
sr
Singapore |
en
Slovakia |
sk
South Africa |
en
Spain |
es
Sweden |
sv
Switzerland |
de
Switzerland |
fr
Taiwan |
zh
Turkey |
tr
United Kingdom |
en
United States |
en
Venezuela |
es
Menu
About
Novartis in the US
Company at a Glance
By the Numbers
Diversity and Inclusion
Pay Transparency-EPIC
Our Code of Ethics
Strategy
Diversity and Inclusion
Ensuring Equity
The Spirit of Inclusivity
Toward a better society
Parental Leave
Standing for Racial Equity and Justice as One Novartis
Novartis US EEO / D&I Report 2021
Supplier Diversity
People and Culture
Products
Country Leadership Team
External Funding
Contact Us
About
Patients and Caregivers
Novartis Commitment to Patients and Caregivers
Patient Assistance
Diseases
Participating in Clinical Trials
Patient Perspectives
Adverse Event Reporting
The STEP Program
Sickle Cell Disease (SCD)
Program Overview
Multiple Sclerosis (MS)
Cancer
Application for Funding to Help Address Health Disparities
Health Disparities
Patients and Caregivers
Healthcare Professionals
Novartis Pipeline
Novartis Clinical Trials
Adverse Event Reporting
Healthcare Professionals
ESG
Ethical Behavior
Code of Ethics
SpeakUp
PhRMA Code on Interactions with Healthcare Professionals
Business Principles
Ethics, Risk and Compliance
Compliance Program
State Laws
Corporate Integrity Agreement
Payments to HCPs & HCOs
Enhanced Verification Request
Corporate Responsibility
Population Health
Novartis in Society US Reports
Novartis US Foundation
Environmental Sustainability
People and Communities
Beacon of Hope
Beacon of Hope: Measurable solutions for health equity
ESG
News
News Archive
Statements
Stories
Contacts
News
Careers
Career Search
Meet the Teams
Early Career
Personal Growth
How We Work
Employee Benefits
Diversity and Inclusion
Awards & Recognition
Careers
Coronavirus
Coronavirus
Home
Novartis presents pivotal Phase III APPLY-PNH data at ASH demonstrating investigational oral monotherapy iptacopan superiority over anti-C5
Reimagine Medicine
Innovation
Novartis investigational iptacopan provides clinically meaningful increases in hemoglobin levels in complement-inhibitor-naïve patients with PNH
Reimagine Medicine
Innovation
Novartis Kisqali® prolonged PFS benefit for pre- and perimenopausal patients with aggressive HR+/HER2− metastatic breast cancer compared to chemotherapy
Reimagine Medicine
Innovation
Novartis highlights scientific advances with Kisqali, iptacopan, Scemblix and YTB323 data at SABCS and ASH
Reimagine Medicine
Innovation
Novartis Scemblix®, with novel mechanism of action, shows superior, long-term efficacy and consistent tolerability in 96-week follow-up of chronic myeloid leukemia trial
Reimagine Medicine
Innovation
Novartis expands Beacon of Hope through alliances with Historically Black Medical Schools to address systemic health disparities
Reimagine Medicine
Innovation
Novartis presents new four-year data on efficacy and safety of Kesimpta® (ofatumumab) in people living with relapsing multiple sclerosis
Reimagine Medicine
Innovation
Novartis acquires Kedalion Therapeutics and its innovative ocular delivery platform that could transform patient experience
Reimagine Medicine
Innovation
2004 Release
Reimagine Medicine
Innovation
2005 Release
Reimagine Medicine
Innovation
News Release 1 Headline
Reimagine Medicine
Innovation
Photo: New Data Show Gleevec® Halts Progression to Advanced Stages of Life-Threatening Form of Leukemia in Sixth Year of Treatment
Reimagine Medicine
Innovation
Pagination
1
2
3
4
5
6
7
8
9
…
›
Next page